πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10933042

Intravenous baclofen formulations and treatment methods

Regents of the University of Minnesota Β· Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10933066

Methods and compositions for treatment of Zika virus infection

BioCryst Pharmaceuticals, Inc. Β· Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10927088

Thymoquinone derivatives for treatment of cancer

UNITED ARAB EMIRATES UNIVERSITY Β· Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10927435

Compositions for the treatment of rheumatoid arthritis and methods of using same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10928391

CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10918594

Controlled-release CNS modulating compositions and methods for the treatment of otic disor

The Regents of the University of California Β· Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10918657

Treatment of spinal cord injury or traumatic brain injury by inhibition of synuclein prote

The Board of Regents of the University of Texas System Β· Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10913947

Antisense oligomers for treatment of conditions and diseases

STOKE THERAPEUTICS, INC. Β· Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10913740

JAK kinase inhibitor compounds for treatment of respiratory disease

Theravance Biopharma R&D IP, LLC Β· Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10913946

RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenn

BIOMARIN TECHNOLOGIES B.V. Β· Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10912834

Topical formulations based on ionic species for skin treatment

The Regents of the University of California Β· Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10906928

Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

Atea Pharmaceuticals, Inc. Β· Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10905690

Treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. Β· Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10905770

Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment o

MacRegen, Inc. Β· Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10898505

Reagents for treatment of hepatitis B virus (HBV) infection and use thereof

Benitec Biopharma Limited Β· Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10899710

Pyridines and their use in the treatment of cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10894044

Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer

The Board of Regents of the University of Texas System Β· Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10894077

Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10894804

Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

Atea Pharmaceuticals, Inc. Β· Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10889576

Phthalazinone compounds and methods for the treatment of cystic fibrosis

Flatley Discovery Lab, LLC Β· Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10888554

Salts of heterocyclic modulators of HIF activity for treatment of disease

The Board of Regents of the University of Texas System Β· Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10881698

Diagnosis and treatment for respiratory tract diseases

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10881708

Ang (1-7) derivative oligopeptides for the treatment of pain

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10881653

Tricyclic compounds and their use in the treatment of cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted